cnf-2024 has been researched along with Lung-Neoplasms* in 3 studies
3 other study(ies) available for cnf-2024 and Lung-Neoplasms
| Article | Year |
|---|---|
Ring-opening of five-membered heterocycles conjugated 4-isopropylresorcinol scaffold-based benzamides as HSP90 inhibitors suppressing tumor growth in vitro and in vivo.
Topics: Afatinib; Animals; Antineoplastic Agents; Benzamides; Cell Cycle Checkpoints; Cell Line; Cell Membrane Permeability; Cell Movement; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Drug Stability; ErbB Receptors; Half-Life; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Rats; Resorcinols; Transplantation, Heterologous | 2021 |
Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Histone Deacetylase 6; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Isoindoles; Lung Neoplasms; Male; Mice, Inbred BALB C; Molecular Docking Simulation; Protein Binding; Xenograft Model Antitumor Assays | 2020 |
Fluoropyrimidin-2,4-dihydroxy-5-isopropylbenzamides as antitumor agents against CRC and NSCLC cancer cells.
A major cause of failure of therapy in patients with non-small cell lung cancer (NSCLC) is development of acquired drug resistance leading to tumor recurrence and disease progression. In addition to the development of new generations of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), different molecular targets may provide opportunities to improve the therapeutic outcomes. In this study, we utilized the core structure 5-fluorouracil (5-FU) or tegafur, a 5-FU prodrug combined through different linkers with resorcinol to generate a series of fluoropyrimidin-2,4-dihydroxy-5-isopropylbenzamides which inhibit potent Heat Shock Protein 90 (HSP90). These compounds were found to show significant antiproliferative activity in colorectal cancer (CRC) HCT116 and NSCLC A549, H460, and H1975 (EGFR L858R/T790 M double mutation) cells. Compound 12c, developed by molecular docking analysis and enzymatic assays exhibits promising inhibitory activity of HSP90. This compound, 12c shows the most potent HSP90 inhibitory activity with an IC Topics: Antineoplastic Agents; Apoptosis; Benzamides; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Colorectal Neoplasms; Cytoprotection; Enzyme Activation; ErbB Receptors; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mutation; Proteolysis; Proto-Oncogene Proteins c-akt | 2020 |